- Home
- LFVN vs ZNTL Comparison
LFVN vs ZNTL Comparison
Compare LFVN & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFVN
- ZNTL
- Stock Information
- Founded
- LFVN N/A
- ZNTL 2014
- Country
- LFVN United States
- ZNTL United States
- Employees
- LFVN N/A
- ZNTL N/A
- Industry
- LFVN Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- LFVN Health Care
- ZNTL Health Care
- Exchange
- LFVN Nasdaq
- ZNTL Nasdaq
- Market Cap
- LFVN 145.2M
- ZNTL 118.3M
- IPO Year
- LFVN N/A
- ZNTL 2020
- Fundamental
- Price
- LFVN $6.56
- ZNTL $1.39
- Analyst Decision
- LFVN Strong Buy
- ZNTL Buy
- Analyst Count
- LFVN 2
- ZNTL 7
- Target Price
- LFVN $30.50
- ZNTL $6.17
- AVG Volume (30 Days)
- LFVN 193.5K
- ZNTL 696.6K
- Earning Date
- LFVN 11-04-2025
- ZNTL 11-10-2025
- Dividend Yield
- LFVN 2.72%
- ZNTL N/A
- EPS Growth
- LFVN 143.91
- ZNTL N/A
- EPS
- LFVN 0.78
- ZNTL N/A
- Revenue
- LFVN $228,877,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- LFVN $6.93
- ZNTL N/A
- Revenue Next Year
- LFVN $1.43
- ZNTL N/A
- P/E Ratio
- LFVN $8.49
- ZNTL N/A
- Revenue Growth
- LFVN 16.77
- ZNTL N/A
- 52 Week Low
- LFVN $5.98
- ZNTL $1.01
- 52 Week High
- LFVN $27.38
- ZNTL $4.00
- Technical
- Relative Strength Index (RSI)
- LFVN 34.81
- ZNTL 48.04
- Support Level
- LFVN $5.98
- ZNTL $1.30
- Resistance Level
- LFVN $7.47
- ZNTL $1.39
- Average True Range (ATR)
- LFVN 0.49
- ZNTL 0.09
- MACD
- LFVN 0.05
- ZNTL 0.01
- Stochastic Oscillator
- LFVN 36.84
- ZNTL 85.92
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.